100 results
Page 2 of 5
PRE 14A
faj1fymqgx
3 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.2
5le59c
10 Nov 22
Passage Bio Reports Third Quarter 2022 Financial Results And Provides Business Updates
7:03am
8-K
EX-99.2
objeumy30 d6x
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
8-K
7rb 8l164be
1 Jun 22
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.2
oth0n20 xqaq1
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
POS AM
3m92aaa1ogvzyvrgt6i
3 Mar 22
Prospectus update (post-effective amendment)
8:29am
POSASR
w6nz y1aveo
3 Mar 22
Automatic shelf registration (post-effective amendment)
7:00am
8-K
EX-99.2
48qf2si
11 Feb 22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium
11:00am
8-K
EX-99.2
pepxf
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
8-K
EX-99.2
861lsev94s1xkyv2
17 Dec 21
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 Gangliosidosis
7:01am